Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Abstract Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-04-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01259-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849733377526071296 |
|---|---|
| author | Carlyn Rose Tan Sireesha Asoori Chiung-Yu Huang Larissa Brunaldi Rakesh Popat Efstathios Kastritis Joaquin Martinez-Lopez Radhika Bansal Andre De Menezes Silva Corraes Saurabh Chhabra Ricardo Parrondo Sikander Ailawadhi Despina Fotiou Meletios A. Dimopoulos Kwee Yong Catriona Mactier Chris Lau Magdalena Corona Adolfo Jesús Sáez Marin Hira Mian Brian GM. Durie Saad Z. Usmani Thomas G. Martin Yi Lin |
| author_facet | Carlyn Rose Tan Sireesha Asoori Chiung-Yu Huang Larissa Brunaldi Rakesh Popat Efstathios Kastritis Joaquin Martinez-Lopez Radhika Bansal Andre De Menezes Silva Corraes Saurabh Chhabra Ricardo Parrondo Sikander Ailawadhi Despina Fotiou Meletios A. Dimopoulos Kwee Yong Catriona Mactier Chris Lau Magdalena Corona Adolfo Jesús Sáez Marin Hira Mian Brian GM. Durie Saad Z. Usmani Thomas G. Martin Yi Lin |
| author_sort | Carlyn Rose Tan |
| collection | DOAJ |
| description | Abstract Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46–61%) and 73% (67–80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33–55%] vs 63% [54–73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1. |
| format | Article |
| id | doaj-art-b63a6e2818094d2eb4c26f3e140b74f2 |
| institution | DOAJ |
| issn | 2044-5385 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-b63a6e2818094d2eb4c26f3e140b74f22025-08-20T03:08:02ZengNature Publishing GroupBlood Cancer Journal2044-53852025-04-0115111010.1038/s41408-025-01259-zReal-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group StudyCarlyn Rose Tan0Sireesha Asoori1Chiung-Yu Huang2Larissa Brunaldi3Rakesh Popat4Efstathios Kastritis5Joaquin Martinez-Lopez6Radhika Bansal7Andre De Menezes Silva Corraes8Saurabh Chhabra9Ricardo Parrondo10Sikander Ailawadhi11Despina Fotiou12Meletios A. Dimopoulos13Kwee Yong14Catriona Mactier15Chris Lau16Magdalena Corona17Adolfo Jesús Sáez Marin18Hira Mian19Brian GM. Durie20Saad Z. Usmani21Thomas G. Martin22Yi Lin23Memorial Sloan Kettering Cancer CenterUniversity of CaliforniaUniversity of CaliforniaMayo ClinicUniversity College LondonDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of MedicineUniversity of Complutense, Hospital 12 de Octubre, CNIO, i + 12Mayo ClinicMayo ClinicMayo ClinicMayo ClinicMayo ClinicDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of MedicineDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of MedicineUniversity College LondonUniversity College LondonUniversity College LondonUniversity of Complutense, Hospital 12 de Octubre, CNIO, i + 12University of Complutense, Hospital 12 de Octubre, CNIO, i + 12McMaster UniversityCedars-Sinai Medical CenterMemorial Sloan Kettering Cancer CenterUniversity of CaliforniaMayo ClinicAbstract Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46–61%) and 73% (67–80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33–55%] vs 63% [54–73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1.https://doi.org/10.1038/s41408-025-01259-z |
| spellingShingle | Carlyn Rose Tan Sireesha Asoori Chiung-Yu Huang Larissa Brunaldi Rakesh Popat Efstathios Kastritis Joaquin Martinez-Lopez Radhika Bansal Andre De Menezes Silva Corraes Saurabh Chhabra Ricardo Parrondo Sikander Ailawadhi Despina Fotiou Meletios A. Dimopoulos Kwee Yong Catriona Mactier Chris Lau Magdalena Corona Adolfo Jesús Sáez Marin Hira Mian Brian GM. Durie Saad Z. Usmani Thomas G. Martin Yi Lin Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study Blood Cancer Journal |
| title | Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study |
| title_full | Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study |
| title_fullStr | Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study |
| title_full_unstemmed | Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study |
| title_short | Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study |
| title_sort | real world evaluation of teclistamab for the treatment of relapsed refractory multiple myeloma rrmm an international myeloma working group study |
| url | https://doi.org/10.1038/s41408-025-01259-z |
| work_keys_str_mv | AT carlynrosetan realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT sireeshaasoori realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT chiungyuhuang realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT larissabrunaldi realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT rakeshpopat realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT efstathioskastritis realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT joaquinmartinezlopez realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT radhikabansal realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT andredemenezessilvacorraes realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT saurabhchhabra realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT ricardoparrondo realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT sikanderailawadhi realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT despinafotiou realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT meletiosadimopoulos realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT kweeyong realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT catrionamactier realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT chrislau realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT magdalenacorona realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT adolfojesussaezmarin realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT hiramian realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT briangmdurie realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT saadzusmani realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT thomasgmartin realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy AT yilin realworldevaluationofteclistamabforthetreatmentofrelapsedrefractorymultiplemyelomarrmmaninternationalmyelomaworkinggroupstudy |